Lucrin depot

PreclinicalSmall molecule

AAntalya IVF

Lucrin depot is one of 4 small molecule programs targeting Blastocyst. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BlastocystWithdrawn

BlastocystPreclinical

Withdrawn

Competition

Competitive Landscape

3 competitors in Blastocyst

#DrugCompanyPhaseTrials

Gnrh Ant

Merck & Co.

Phase 3

1 2

Growth Hormone

Pfizer

Phase 3

1 3

Hcg

Changchun GeneScience Pharmaceutical Co., Ltd.

Preclinical

1 4

Lucrin depot

AAntalya IVF

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Blastocyst1 trial

Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers

Withdrawn·AAntalya IVF·N/A·NCT02238431

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lucrin depot. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lucrin depot compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lucrin depot. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Antalya IVF company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAntalya IVF

Lucrin depot

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Blastocyst1 trial

References

Drug Info

Quick Facts

Related News